Answer
Benralizumab binds IL-5 receptor alpha on eosinophils and basophils and, through high-affinity binding to FcγRIII receptors on immune effector cells such as natural killer cells, enhances antibody-dependent cell-mediated cytotoxicity, causing eosinophil and basophil apoptosis and reducing eosinophilic inflammation.
Sources for this answer
- Fasenra 30 mg solution for injection in pre filled penAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 9Document updated
Sources checked